• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·UK·Healthcare·FDBK.L
Share

Feedback plc Stocks

£ 6.75Last Updated 09.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

£ 3.80M

£ 6.75
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Feedback plc is a medical technology company, headquartered in London, UK, and established in 1958, that supplies specialized software and systems to individuals and organizations working within the medical imaging sector. Their product portfolio includes TexRAD, a patented software tool designed to extract and quantify textural features within radiological images. This assists research into all types of tumors and helps uncover biomarkers in medical imagery. They also offer TexRAD Lung, a specific software tool used for the clinical analysis of lung cancer within the European Union. Additionally, the company provides the Cadran image platform, a robust picture archiving and communication system (PACS) for hospitals and research institutes, capable of handling images from various imaging modalities like CT and PET scanners. Another key offering is Bleepa, a secure platform for clinical communications that facilitates the safe sharing of high-quality medical images.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.07.2026 23:06

Delta's profits were eaten up by record fuel costs. But revenue was buoyed by demand

10.07.2026 21:56

An Unwelcome Measure: Why Kazakhstan Is Abolishing the Mandatory Sale of Foreign Currency Proceeds

10.07.2026 20:51

SK Hynix shares rose 14% to $170 at the start of trading on their debut

10.07.2026 20:07

Trump announced that negotiations with Iran would continue. But he added: “The truce is over.”

10.07.2026 19:45

Plenty of Oil, but No Gasoline: The IEA Warned That Consumption Will Fall for the First Time Since 2020

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026